Viewpoint: After the options expiration on March 20, there is significant funding betting on BTC surging to $75,000
BlockBeats News, March 16th, according to crypto analyst Murphy, looking at the March 20th expiry Gamma Exposure (GEX), there is around $180 million of Gamma exposure near $74,000, in a Long Gamma structure. In this environment, market makers' hedging behavior usually suppresses volatility, making the price more likely to oscillate around that strike price, effectively creating resistance near $74,000. However, after March 20th, until the next major expiry on March 27th, a significant shift in the options structure has occurred. Call OI is significantly higher than Put, indicating that a large amount of funds in the market are betting that BTC will rise towards $75,000.
Murphy believes that after the March 20th expiry, BTC's options structure will make $75,000 the new focus, transitioning from the previous 'suppressed volatility' to 'amplified volatility,' generating resistance as it approaches $80,000 and support in the $65,000-67,000 range.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley senior bond investor turns bullish on US Treasuries for the first time in ten years
US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46
SuperX AI Technology's stock price declined, falling more than 2.5% at one point.
BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars
Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)
Crypto prices
More
